Pharma BD Deal Intelligence
Eli Lilly and Boehringer Ingelheim established a broad diabetes alliance to jointly develop and commercialize a portfolio of diabetes compounds, anchored by empagliflozin (Jardiance), an SGLT2 inhibitor, and linagliptin (Tradjenta), a DPP-4 inhibitor. The alliance structure involves 50/50 cost and revenue sharing globally. BI contributes the compounds and Lilly contributes its diabetes commercial infrastructure. Financial terms were not fully disclosed but the combined portfolio has generated over $10B in annual revenue.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Boehringer Ingelheim GmbH (this deal) | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
| Eli Lilly and Company / Hanmi Pharmaceutical Co. Ltd. | 2026 | $1.3B | 65 |
← Browse all deals · How we score deals
More: 2011 deals · Eli Lilly and Company deals · Cardiovascular deals